CTIS2023-505859-45-00招募中1 期
Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery. - AP-recAP-CSA-RD-0201
AM-Pharma B.V.0 个研究点目标入组 212 人开始时间: 2023年8月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 212
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age =18 years, Planned for one of the following types of open chest cardiovascular surgery with the use of cardiopulmonary bypass pump (CPB): a. 1) combined valve and CABG surgery 2) aortic valve plus aortic root and/or ascending aorta (excluding aortic arch) b. CABG with 3 or more distal anastomoses, Screening eGFR =25 mL/min/1.73m2 and =65 mL/min/1.73m2 (calculated at Screening using sCreat which can be maximally 28 days old and the 2021 CKD-EPI formula without race correction (eGFR = 142 × Min(Scr/?,1)a × Max(Scr/?,1)-1.200 × 0.9938Age [× 1.012 if female]), Female patients of childbearing potential agreeing to use an effective contraception method within IP treatment and 14 days thereafter. Post-menopausal females (i.e., >60 years of age or no menses for 12 consecutive months without an alternative medical cause with confirmatory follicle-stimulating hormone level of =40 mIU/mL) do not require contraception during the trial., Male patients agreeing to refrain from donating sperm, use a male condom when having sexual intercourse and in case their partner is of childbearing potential they must agree to use adequate and effective contraception method (see inclusion criterion 4) within IP treatment and 14 days thereafter
排除标准
- •Body weight =55 kg, Not willing and able to understand the information on the nature, the scope, and the relevance of the trial and to provide voluntary, written informed consent to participate in the trial before any trial related procedures, Pregnant or nursing women, Known or suspected hypersensitivity to ilofotase alfa or any components of the formulation used, Any previous organ transplantation, Congenital heart disease, Diagnosed with AKI (as defined by KDIGO criteria) within 3 months prior to surgery, History of RRT, Cardiogenic shock or hemodynamic instability which require inotropes or vasopressors or other mechanical devices such as intra-aortic balloon counter-pulsation (IABP) within 24 hours prior to surgery, A requirement for any of the following within one week prior to surgery: implantation of a defibrillator or permanent pacemaker, mechanical ventilation, IABP, LVAD, other forms of mechanical circulatory support, Required cardiopulmonary resuscitation within 14 days prior to cardiac surgery, Known or suspected glomerulonephritis (other than diabetic kidney disease) or other systemic vasculitis, Ongoing sepsis (as defined by SEPSIS-3, the Third International Consensus Definitions for Sepsis and Septic Shock) within the past 2 weeks or, in the opinion of the investigator, an untreated diagnosed clinically significant infection (viral or bacterial) prior to or at Screening and before randomization, Medical condition which requires active immunosuppressive treatment (daily steroid doses of =10 mg are allowed), Employees or relatives of the sponsor or the investigator, Confirmed or treated endocarditis requiring antimicrobial or antiviral treatment within 30 days prior to surgery or other current active infection requiring antimicrobial or antiviral treatment within 14 days prior to surgery, Known chronic liver disorder with Child-Pugh C classification, Current planned (or scheduled) surgical intervention under conditions of circulatory arrest, including planned deep hypothermic circulatory arrest, Planned surgery for aortic dissection, Use of left ventricular assist device (LVAD), or intra-aortic balloon pump or other cardiac devices, within 7 days prior to surgery, Received any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to Day 1 or planned or current participation in another interventional study until the EoT visit has been completed, Previous receipt of ilofotase alfa
研究者
相似试验
进行中（未招募）
1 期
Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous PemphigoidEUCTR2019-001059-37-DEAlkahest, Inc.30
进行中（未招募）
1 期
Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous PemphigoidEUCTR2019-001059-37-BGAlkahest, Inc.10
进行中（未招募）
不适用
The Effects of Vegetable Soup on the Gut Microbiomeow dietary fibre consumptionLow dietary fibre consumptionDiet and Nutrition - Other diet and nutrition disordersOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12619001149156Australian Health & Nutrition Association Limited48
进行中（未招募）
不适用
Ferric Carboxymaltose Versus Placebo in Patients with Congestive Heart FailureEUCTR2012-001134-33-DEniversitätsklinikum Ulm
已完成
不适用
Effectivenessof L-Arginine supplementation for treatment of patients with pulmonary tuberculosisTuberculosis.Tuberculosis of lung, confirmed by sputum microscopy with or without cultureIRCT201211179855N2Arak University of Medical Sciences60